

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
BLA 125276/S049

OTHER REVIEW(S)

DMEPA

**Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology
Office of Medication Error Prevention and Risk Management**

Label, Labeling and Packaging Review

Date: August 6, 2012

Reviewer(s): Lissa C. Owens, PharmD
Division of Medication Error Prevention and Analysis

Team Leader Lubna Merchant, M.S., PharmD
Division of Medication Error Prevention and Analysis

Associate Director Scott Dallas, RPh
Division of Medication Error Prevention and Analysis

Drug Name(s) and Strength(s): Actemra (Tocilizumab)
Injection
80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL

Application Type/Number: BLA 125276/S-049

Applicant/sponsor: Hoffman-Roche

OSE RCM #: 2012-290

*** This document contains proprietary and confidential information that should not be released to the public.***

Contents

1	Introduction.....	1
1.1	Regulatory History.....	1
1.2	Product Information.....	1
2	Methods and Materials Reviewed.....	1
2.1	Selection of Medication Error Cases.....	2
2.2	Labels and Labeling.....	2
2.3	Previously Completed Reviews.....	2
3	Conclusions.....	2
4	References.....	3
	Appendices.....	4
	Appendix A. Database Descriptions.....	4

1 INTRODUCTION

This review evaluates the proposed insert labeling for Actemra (Tocilizumab) Injection BLA 125276 for areas of vulnerability that could lead to medication errors. The Applicant submitted a (b) (4) supplement for the proposed new indication for adult patients with moderately to severely active Rheumatoid Arthritis who has an inadequate response to (b) (4)

1.1 REGULATORY HISTORY

Actemra Injection was approved on January 8, 2010 (BLA 125276) for the indication of treatment of Rheumatoid Arthritis in adult patients with moderately to severely active Rheumatoid Arthritis who have had an inadequate response to one or more TNF antagonist therapies and Systemic Juvenile Idiopathic Arthritis in patients 2 years of age and older.

1.2 PRODUCT INFORMATION

The following product information is included in the approved labeling dated January 8, 2010.

- Active Ingredient: Tocilizumab
- Indication of Use: Rheumatoid Arthritis in adult patients with moderately to severely active Rheumatoid Arthritis who have had an inadequate response to one or more TNF antagonist therapies and Systemic Juvenile Idiopathic Arthritis in patients 2 years of age and older
- Route of Administration: Intravenous
- Dosage Form: Injection Solution
- Strength: 80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL
- Dose and Frequency: Adults (Every 4 weeks): When used in combination with DMARD's or as monotherapy 4 mg per kg followed by an increase to 8 mg per kg based on clinical response. SJIA (every 2 weeks) patients less than 30 kg: 12 mg per kg. Patients at or above 30 kg: 8 mg per kg
- How Supplied: single-use preservative free vials
- Storage: Must be refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze and protect from light

2 METHODS AND MATERIALS REVIEWED

DMEPA searched the FDA Adverse Event Reporting System (AERS) database for Actemra medication error reports. We also reviewed the Actemra package insert labeling submitted by the Applicant.

2.1 SELECTION OF MEDICATION ERROR CASES

We searched the FDA Adverse Event Reporting System (AERS) database using the strategy listed in Table 1.

Date	No limitation set
Drug Names	(Tocilizumab) (Actemra) (Actem%)
MedDRA Search Strategy	Medication Errors (HLGT) Product Quality Issue (PT)

The AERS database searches identified 7 reports. Each report was reviewed for relevancy and duplication. After individual review, all 7 reports were not included in the final analysis for the following reasons:

- Adverse reactions (n=6)
- Overdose (n=1) unrelated to label and labeling

2.2 LABELS AND LABELING

Using the principals of human factors and Failure Mode and Effects Analysis,¹ along with post marketing medication error data, the Division of Medication Error Prevention and Analysis (DMEPA) evaluated the following:

- Insert Labeling submitted December 12, 2011

2.3 PREVIOUSLY COMPLETED REVIEWS

DMEPA had previously reviewed Actemra (OSE RCM # 2010-2255) and we looked at the review to ensure all our recommendation were implemented.

3 CONCLUSIONS

The Applicant proposes to introduce a new indication for adult patients with (b) (4). The dose and frequency of Actemra will remain the same. Therefore DMEPA concludes that the changes to the prescribing information are adequate for a medication error safety standpoint. We do not have any recommendations at this time.

If you have further questions or need clarifications, please contact Nichelle Rashid, project manager, at 301-796-3904

¹ Institute for Healthcare Improvement (IHI). Failure Modes and Effects Analysis. Boston. IHI:2004.

4 REFERENCES

OSE Review # 2010-2255, Labeling Review for Actemra (Tocilizumab) Injection, Baksh, Charlene. January 10, 2011

APPENDICES

APPENDIX A. DATABASE DESCRIPTIONS

Adverse Event Reporting System (AERS)

The Adverse Event Reporting System (AERS) is a computerized information database designed to support the FDA's post-marketing safety surveillance program for drug and therapeutic biologic products. The FDA uses AERS to monitor adverse events and medication errors that might occur with these marketed products. The structure of AERS complies with the international safety reporting guidance (ICH E2B) issued by the International Conference on Harmonisation. Adverse events in AERS are coded to terms in the Medical Dictionary for Regulatory Activities terminology (MedDRA).

AERS data do have limitations. First, there is no certainty that the reported event was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. Further, FDA does not receive all adverse event reports that occur with a product. Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event. Therefore, AERS cannot be used to calculate the incidence of an adverse event in the U.S. population.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LISSA C OWENS
08/06/2012

LUBNA A MERCHANT
08/06/2012

SCOTT M DALLAS
08/06/2012

**Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Policy Initiatives
Division of Medical Policy Programs**

PATIENT LABELING REVIEW

Date: **September 24, 2012**

To: **Badrul Chowdhury, MD,
Director
Division of Pulmonary, Allergy, Rheumatology Products
(DPARP)**

Through: **LaShawn Griffiths, MSHS-PH, BSN, RN
Associate Director for Patient Labeling
Division of Medical Policy Programs (DMPP)**

**Melissa Hulett, RN, BSN, MSBA
Team Leader, Patient Labeling Team
Division of Medical Policy Programs (DMPP)**

From: **Sharon W. Williams, RN, BSN, MSN
Patient Labeling Reviewer
Division of Medical Policy Programs (DMPP)**

Subject: **DMPP Review of Patient Labeling: Medication Guide (MG)**

Drug Name (established name): **Actemra (tocilizumab)**

Dosage Form and Route: **Injection for Intravenous Infusion**

Application Type/Number: **BLA 125276**

Supplement Number: **S-049**

Applicant: **Hoffman-La Roche Incorporated**

1 INTRODUCTION

Actemra was originally approved on January 8, 2010 for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

On December 12, 2011, Hoffman-LaRoche Incorporated submitted a new efficacy supplement with a new indication. The new indication is for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying-Anti-Rheumatic Drugs (DMARDs).

On January 30, 2012 the Division of Pulmonary, Allergy, and Rheumatology Products (DPARP) requested that the Division of Medical Policy Programs (DMPP) review the Applicant's proposed Medication Guide for ACTEMRA (tocilizumab).

This memorandum documents the DMPP review and concurrence with the Applicant's proposed Medication Guide (MG).

Actemra was initially approved January 8, 2010, as a REMS with a Medication Guide and Communication Plan. The April 15, 2011, approval removed the Medication Guide from the REMS; however, retained the Medication Guide as part of approved labeling in accordance with 21 CFR 208.

2 MATERIAL REVIEWED

- Draft ACTEMRA (tocilizumab) Injection for Intravenous Infusion MG submitted on September 12, 2012 and received by DMPP on September 18, 2012.
- Draft ACTEMRA (tocilizumab) Injection for Intravenous Infusion Prescribing Information (PI) submitted on September 12, 2012, revised throughout the current review cycle and received by DMPP on September 18, 2012.
- Approved ACTEMRA (tocilizumab) Injection for Intravenous Infusion MG dated August 13, 2012.

3 CONCLUSION

In our review, we performed a side-by-side review to the Applicant's proposed MG against the currently approved ACTEMRA (tocilizumab) MG dated August 13, 2012 and find the Applicant's proposed MG is acceptable as submitted.

4 RECOMMENDATIONS

- Consult DMPP regarding additional revisions made to the Prescribing Information (PI) to determine if corresponding revisions need to be made to the MG.

Please let us know if you have any questions.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SHARON W WILLIAMS
09/24/2012

MELISSA I HULETT
09/24/2012

LASHAWN M GRIFFITHS
09/24/2012

RPM FILING REVIEW

(Including Memo of Filing Meeting)

To be completed for all new NDAs, BLAs, and Efficacy Supplements [except SE8 (labeling change with clinical data) and SE9 (manufacturing change with clinical data)]

Application Information		
NDA # BLA# 125276	NDA Supplement #-S- BLA Supplement # 49	Efficacy Supplement Type SE- 1
Proprietary Name: Actemra® Established/Proper Name: tocilizumab Dosage Form: intravenous Strengths: 80 mg per 4ml; 200 mg per 10 ml; 400 mg per 20 ml		
Applicant: Genentech, A Member of the Roche Group (Hoffman-LaRoche) Agent for Applicant (if applicable):		
Date of Application: December 12, 2011 Date of Receipt: December 13, 2011 Date clock started after UN:		
PDUFA Goal Date: October 12, 2012	Action Goal Date (if different):	
Filing Date: February 11, 2012	Date of Filing Meeting: January 25, 2012	
Chemical Classification: (1,2,3 etc.) (original NDAs only)		
Proposed indication(s)/Proposed change(s): Adult patients with (b) (4)		
Type of Original NDA: AND (if applicable) Type of NDA Supplement:	<input type="checkbox"/> 505(b)(1) <input type="checkbox"/> 505(b)(2) <input type="checkbox"/> 505(b)(1) <input type="checkbox"/> 505(b)(2)	
<i>If 505(b)(2): Draft the "505(b)(2) Assessment" form found at: http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/ImmediateOffice/UCM027499 and refer to Appendix A for further information.</i>		
Review Classification:	<input checked="" type="checkbox"/> Standard <input type="checkbox"/> Priority <input type="checkbox"/> Tropical Disease Priority Review Voucher submitted	
<i>If the application includes a complete response to pediatric WR, review classification is Priority.</i> <i>If a tropical disease priority review voucher was submitted, review classification is Priority.</i>		
Resubmission after withdrawal? <input type="checkbox"/>		
Resubmission after refuse to file? <input type="checkbox"/>		
Part 3 Combination Product? <input type="checkbox"/>	<input type="checkbox"/> Convenience kit/Co-package <input type="checkbox"/> Pre-filled drug delivery device/system <input checked="" type="checkbox"/> Pre-filled biologic delivery device/system <input type="checkbox"/> Device coated/impregnated/combined with drug <input type="checkbox"/> Device coated/impregnated/combined with biologic <input type="checkbox"/> Drug/Biologic <input type="checkbox"/> Separate products requiring cross-labeling <input type="checkbox"/> Possible combination based on cross-labeling of separate products <input type="checkbox"/> Other (drug/device/biological product)	
<i>If yes, contact the Office of Combination Products (OCP) and copy them on all Inter-Center consults</i>		

<input type="checkbox"/> Fast Track <input type="checkbox"/> Rolling Review <input type="checkbox"/> Orphan Designation <input type="checkbox"/> Rx-to-OTC switch, Full <input type="checkbox"/> Rx-to-OTC switch, Partial <input type="checkbox"/> Direct-to-OTC Other:	<input type="checkbox"/> PMC response <input type="checkbox"/> PMR response: <input type="checkbox"/> FDAAA [505(o)] <input type="checkbox"/> PREA deferred pediatric studies [21 CFR 314.55(b)/21 CFR 601.27(b)] <input type="checkbox"/> Accelerated approval confirmatory studies (21 CFR 314.510/21 CFR 601.41) <input type="checkbox"/> Animal rule postmarketing studies to verify clinical benefit and safety (21 CFR 314.610/21 CFR 601.42)
--	--

Collaborative Review Division (if OTC product):

List referenced IND Number(s): 11972; 10045; 10597; 112406

Goal Dates/Product Names/Classification Properties	YES	NO	NA	Comment
PDUFA and Action Goal dates correct in tracking system? <i>If no, ask the document room staff to correct them immediately. These are the dates used for calculating inspection dates.</i>	✓			
Are the proprietary, established/proper, and applicant names correct in tracking system? <i>If no, ask the document room staff to make the corrections. Also, ask the document room staff to add the established/proper name to the supporting IND(s) if not already entered into tracking system.</i>	✓			
Is the review priority (S or P) and all appropriate classifications/properties entered into tracking system (e.g., chemical classification, combination product classification, 505(b)(2), orphan drug)? <i>For NDAs/NDA supplements, check the Application and Supplement Notification Checklists for a list of all classifications/properties at: http://inside.fda.gov:9003/CDER/OfficeofBusinessProcessSupport/ucm163970.htm</i> <i>If no, ask the document room staff to make the appropriate entries.</i>	✓			
Application Integrity Policy	YES	NO	NA	Comment
Is the application affected by the Application Integrity Policy (AIP)? <i>Check the AIP list at: http://www.fda.gov/ICECI/EnforcementActions/ApplicationIntegrityPolicy/default.htm</i> <i>If yes, explain in comment column.</i>		✓		
<i>If affected by AIP, has OC/DMPQ been notified of the submission? If yes, date notified:</i>				
User Fees	YES	NO	NA	Comment
Is Form 3397 (User Fee Cover Sheet) included with authorized signature?	✓			

<p>User Fee Status</p> <p><i>If a user fee is required and it has not been paid (and it is not exempted or waived), the application is unacceptable for filing following a 5-day grace period. Review stops. Send Unacceptable for Filing (UN) letter and contact user fee staff.</i></p>	<p>Payment for this application:</p> <p><input checked="" type="checkbox"/> Paid <input type="checkbox"/> Exempt (orphan, government) <input type="checkbox"/> Waived (e.g., small business, public health) <input type="checkbox"/> Not required</p>
--	--

<p><i>If the firm is in arrears for other fees (regardless of whether a user fee has been paid for this application), the application is unacceptable for filing (5-day grace period does not apply). Review stops. Send UN letter and contact the user fee staff.</i></p>	<p>Payment of other user fees:</p> <p><input type="checkbox"/> Not in arrears <input type="checkbox"/> In arrears</p>
--	--

505(b)(2) (NDAs/NDA Efficacy Supplements only)	YES	NO	NA	Comment
---	-----	----	----	---------

Is the application for a duplicate of a listed drug and eligible for approval under section 505(j) as an ANDA?				
--	--	--	--	--

Is the application for a duplicate of a listed drug whose only difference is that the extent to which the active ingredient(s) is absorbed or otherwise made available to the site of action is less than that of the reference listed drug (RLD)? [see 21 CFR 314.54(b)(1)].				
---	--	--	--	--

Is the application for a duplicate of a listed drug whose only difference is that the rate at which the proposed product's active ingredient(s) is absorbed or made available to the site of action is unintentionally less than that of the listed drug [see 21 CFR 314.54(b)(2)]?				
---	--	--	--	--

If you answered yes to any of the above questions, the application may be refused for filing under 21 CFR 314.101(d)(9). Contact the (b)(2) review staff in the Immediate Office of New Drugs

Is there unexpired exclusivity on the active moiety (e.g., 5-year, 3-year, orphan or pediatric exclusivity)? Check the Electronic Orange Book at: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm If yes, please list below:				
---	--	--	--	--

Application No.	Drug Name	Exclusivity Code	Exclusivity Expiration

If there is unexpired, 5-year exclusivity remaining on the active moiety for the proposed drug product, a 505(b)(2) application cannot be submitted until the period of exclusivity expires (unless the applicant provides paragraph IV patent certification; then an application can be submitted four years after the date of approval.) Pediatric exclusivity will extend both of the timeframes in this provision by 6 months. 21 CFR 108(b)(2). Unexpired, 3-year exclusivity will only block the approval, not the submission of a 505(b)(2) application.

Exclusivity	YES	NO	NA	Comment
--------------------	-----	----	----	---------

Does another product (same active moiety) have orphan exclusivity for the same indication? Check the Orphan Drug Designations and Approvals list at: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm				
--	--	--	--	--

<p>If another product has orphan exclusivity, is the product considered to be the same product according to the orphan drug definition of sameness [see 21 CFR 316.3(b)(13)]?</p> <p><i>If yes, consult the Director, Division of Regulatory Policy II, Office of Regulatory Policy</i></p>				
<p>Has the applicant requested 5-year or 3-year Waxman-Hatch exclusivity? (<i>NDAs/NDA efficacy supplements only</i>)</p> <p>If yes, # years requested:</p> <p><i>Note: An applicant can receive exclusivity without requesting it; therefore, requesting exclusivity is not required.</i></p>				
<p>Is the proposed product a single enantiomer of a racemic drug previously approved for a different therapeutic use (<i>NDAs only</i>)?</p>				
<p>If yes, did the applicant: (a) elect to have the single enantiomer (contained as an active ingredient) not be considered the same active ingredient as that contained in an already approved racemic drug, and/or (b): request exclusivity pursuant to section 505(u) of the Act (per FDAAA Section 1113)?</p> <p><i>If yes, contact Mary Ann Holovac, Director of Drug Information, OGD/DLPS/LRB.</i></p>				

Format and Content				
<p><i>Do not check mixed submission if the only electronic component is the content of labeling (COL).</i></p>	<input type="checkbox"/> All paper (except for COL) <input type="checkbox"/> All electronic <input checked="" type="checkbox"/> Mixed (paper/electronic) <input type="checkbox"/> CTD <input type="checkbox"/> Non-CTD <input type="checkbox"/> Mixed (CTD/non-CTD)			
<p>If mixed (paper/electronic) submission, which parts of the application are submitted in electronic format?</p>	Admin forms; labeling; Risk Mgmt Plan; Ped Information; References; Correspondences			
Overall Format/Content	YES	NO	NA	Comment
<p>If electronic submission, does it follow the eCTD guidance?¹ If not, explain (e.g., waiver granted).</p>				
<p>Index: Does the submission contain an accurate comprehensive index?</p>	✓			
<p>Is the submission complete as required under 21 CFR 314.50 (<i>NDAs/NDA efficacy supplements</i>) or under 21 CFR 601.2 (<i>BLAs/BLA efficacy supplements</i>) including:</p>	✓			

¹

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072349.pdf>

<input checked="" type="checkbox"/> legible <input checked="" type="checkbox"/> English (or translated into English) <input checked="" type="checkbox"/> pagination <input checked="" type="checkbox"/> navigable hyperlinks (electronic submissions only)				
If no, explain.				
BLAs only: Companion application received if a shared or divided manufacturing arrangement?			✓	
If yes, BLA #				
Forms and Certifications				
<i>Electronic forms and certifications with electronic signatures (scanned, digital, or electronic – similar to DARRTS, e.g., /s/) are acceptable. Otherwise, paper forms and certifications with hand-written signatures must be included. Forms include: user fee cover sheet (3397), application form (356h), patent information (3542a), financial disclosure (3454/3455), and clinical trials (3674); Certifications include: debarment certification, patent certification(s), field copy certification, and pediatric certification.</i>				
Application Form	YES	NO	NA	Comment
Is form FDA 356h included with authorized signature per 21 CFR 314.50(a)?	✓			
<i>If foreign applicant, a U.S. agent must sign the form [see 21 CFR 314.50(a)(5)].</i>				
Are all establishments and their registration numbers listed on the form/attached to the form?				
Patent Information (NDAs/NDA efficacy supplements only)	YES	NO	NA	Comment
Is patent information submitted on form FDA 3542a per 21 CFR 314.53(c)?				
Financial Disclosure	YES	NO	NA	Comment
Are financial disclosure forms FDA 3454 and/or 3455 included with authorized signature per 21 CFR 54.4(a)(1) and (3)?		✓		Financial disclosures for the clinical long term extension studies in this supplement do not qualify as covered studies per the guidance on financial disclosures
<i>Forms must be signed by the APPLICANT, not an Agent [see 21 CFR 54.2(g)].</i>				
<i>Note: Financial disclosure is required for bioequivalence studies that are the basis for approval.</i>				
Clinical Trials Database	YES	NO	NA	Comment
Is form FDA 3674 included with authorized signature?	✓			
<i>If yes, ensure that the application is also coded with the supporting document category, "Form 3674."</i>				
<i>If no, ensure that language requesting submission of the form is included in the acknowledgement letter sent to the applicant</i>				
Debarment Certification	YES	NO	NA	Comment
Is a correctly worded Debarment Certification included with authorized signature?	✓			

<p>Certification is not required for supplements if submitted in the original application; If foreign applicant, both the applicant and the U.S. Agent must sign the certification [per Guidance for Industry: Submitting Debarment Certifications].</p> <p><i>Note: Debarment Certification should use wording in FDCA Section 306(k)(1) i.e., "[Name of applicant] hereby certifies that it did not and will not use in any capacity the services of any person debarred under section 306 of the Federal Food, Drug, and Cosmetic Act in connection with this application." Applicant may not use wording such as, "To the best of my knowledge..."</i></p>				
<p>Field Copy Certification (NDAs/NDA efficacy supplements only)</p>	YES	NO	NA	Comment
<p>For paper submissions only: Is a Field Copy Certification (that it is a true copy of the CMC technical section) included?</p> <p><i>Field Copy Certification is not needed if there is no CMC technical section or if this is an electronic submission (the Field Office has access to the EDR)</i></p> <p><i>If maroon field copy jackets from foreign applicants are received, return them to CDR for delivery to the appropriate field office.</i></p>				

<p>Controlled Substance/Product with Abuse Potential</p>	YES	NO	NA	Comment
<p><u>For NMEs:</u> Is an Abuse Liability Assessment, including a proposal for scheduling, submitted per 21 CFR 314.50(d)(5)(vii)?</p> <p><i>If yes, date consult sent to the Controlled Substance Staff:</i></p> <p><u>For non-NMEs:</u> <i>Date of consult sent to Controlled Substance Staff:</i></p>			✓	

<p>Pediatrics</p>	YES	NO	NA	Comment
<p><u>PREA</u></p> <p>Does the application trigger PREA?</p> <p><i>If yes, notify PeRC RPM (PeRC meeting is required)²</i></p> <p><i>Note: NDAs/BLAs/efficacy supplements for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration trigger PREA. All waiver & deferral requests, pediatric plans, and pediatric assessment studies must be reviewed by PeRC prior to approval of the application/supplement.</i></p>	✓			
<p>If the application triggers PREA, are the required pediatric assessment studies or a full waiver of pediatric studies included?</p>				

² <http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/PediatricandMaternalHealthStaff/ucm027829.htm>

If studies or full waiver not included , is a request for full waiver of pediatric studies OR a request for partial waiver and/or deferral with a pediatric plan included? <i>If no, request in 74-day letter</i>		✓		
If a request for full waiver/partial waiver/deferral is included , does the application contain the certification(s) required by FDCA Section 505B(a)(3) and (4)? <i>If no, request in 74-day letter</i>				
BPCA (NDAs/NDA efficacy supplements only): Is this submission a complete response to a pediatric Written Request? <i>If yes, notify Pediatric Exclusivity Board RPM (pediatric exclusivity determination is required)³</i>				
Proprietary Name	YES	NO	NA	Comment
Is a proposed proprietary name submitted? <i>If yes, ensure that the application is also coded with the supporting document category, "Proprietary Name/Request for Review."</i>			✓	
REMS	YES	NO	NA	Comment
Is a REMS submitted? <i>If yes, send consult to OSE/DRISK and notify OC/OSI/DSC/PMSB via the DCRMSRMP mailbox</i>	✓			
Prescription Labeling	<input type="checkbox"/> Not applicable			
Check all types of labeling submitted.	<input checked="" type="checkbox"/> Package Insert (PI) <input type="checkbox"/> Patient Package Insert (PPI) <input type="checkbox"/> Instructions for Use (IFU) <input checked="" type="checkbox"/> Medication Guide (MedGuide) <input checked="" type="checkbox"/> Carton labels <input type="checkbox"/> Immediate container labels <input type="checkbox"/> Diluent <input type="checkbox"/> Other (specify)			
	YES	NO	NA	Comment
Is Electronic Content of Labeling (COL) submitted in SPL format? <i>If no, request applicant to submit SPL before the filing date.</i>	✓			
Is the PI submitted in PLR format? ⁴	✓			
If PI not submitted in PLR format , was a waiver or deferral requested before the application was received or in				

³ <http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/PediatricandMaternalHealthStaff/ucm027837.htm>

⁴ <http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/StudyEndpointsandLabelingDevelopmentTeam/ucm025576.htm>

If PI not submitted in PLR format , was a waiver or deferral requested before the application was received or in the submission? If requested before application was submitted , what is the status of the request? <i>If no waiver or deferral, request applicant to submit labeling in PLR format before the filing date.</i>				
All labeling (PI, PPI, MedGuide, IFU, carton and immediate container labels) consulted to OPDP?	✓			
MedGuide, PPI, IFU (plus PI) consulted to OSE/DRISK? (send WORD version if available)	✓			
Carton and immediate container labels, PI, PPI sent to OSE/DMEPA and appropriate CMC review office (OBP or ONDQA)?	✓			
OTC Labeling	<input type="checkbox"/> Not Applicable			
Check all types of labeling submitted.	<input type="checkbox"/> Outer carton label <input type="checkbox"/> Immediate container label <input type="checkbox"/> Blister card <input type="checkbox"/> Blister backing label <input type="checkbox"/> Consumer Information Leaflet (CIL) <input type="checkbox"/> Physician sample <input type="checkbox"/> Consumer sample <input type="checkbox"/> Other (specify)			
	YES	NO	NA	Comment
Is electronic content of labeling (COL) submitted? <i>If no, request in 74-day letter.</i>				
Are annotated specifications submitted for all stock keeping units (SKUs)? <i>If no, request in 74-day letter.</i>				
If representative labeling is submitted, are all represented SKUs defined? <i>If no, request in 74-day letter.</i>				
All labeling/packaging, and current approved Rx PI (if switch) sent to OSE/DMEPA?				
Other Consults	YES	NO	NA	Comment
Are additional consults needed? (e.g., IFU to CDRH; QT study report to QT Interdisciplinary Review Team) <i>If yes, specify consult(s) and date(s) sent:</i>		✓		
Meeting Minutes/SPAs	YES	NO	NA	Comment
End-of Phase 2 meeting(s)? Date(s): <i>If yes, distribute minutes before filing meeting</i>				End of Review Mtg- 6/28/10 Written responses- 9/29/11

4

<http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/StudyEndpointsandLabelingDevelopmentTeam/ucm025576.htm>

Pre-NDA/Pre-BLA/Pre-Supplement meeting(s)? Date(s): 11/14/11 <i>If yes, distribute minutes before filing meeting</i>	✓			
Any Special Protocol Assessments (SPAs)? Date(s): <i>If yes, distribute letter and/or relevant minutes before filing meeting</i>		✓		

ATTACHMENT
MEMO OF FILING MEETING

DATE: January 25, 2012

BLA/Supp #: 125276/49

PROPRIETARY NAME: Actemra

ESTABLISHED/PROPER NAME: Tocilizumab

DOSAGE FORM/STRENGTH: Intravenous – 80 mg/4ml; 200 mg/20ml; 400 mg/20ml

APPLICANT: Genentech, A Member of the Roche Group
(Hoffman La Roche)

PROPOSED INDICATION(S)/PROPOSED CHANGE(S): Treatment of adult patients with
(b) (4)

BACKGROUND: This is a filing meeting for a supplemental BLA for Actemra®, an approved product, for the proposed indication that would include patients whom have had an inadequate response to
(b) (4) This change in indication leads to product use as a second line of treatment.

REVIEW TEAM:

Discipline/Organization	Names		Present at filing meeting? (Y or N)
Regulatory Project Management	RPM:	Philantha Bowen	N
	CPMS/TL:	Ladan Jafari	N
Cross-Discipline Team Leader (CDTL)	Sarah Yim		Y
Clinical	Reviewer:	Keith Hull	Y
	TL:	Sarah Yim	Y
Social Scientist Review (for OTC products)	Reviewer:		
	TL:		
OTC Labeling Review (for OTC products)	Reviewer:		
	TL:		
Clinical Microbiology (for antimicrobial products)	Reviewer:		
	TL:		

Clinical Pharmacology	Reviewer:	Elizabeth Shang	Y
	TL:	Suresh Doddapaneni	N
Biostatistics	Reviewer:	David Hoberman	N
	TL:	Joan Buenconsejo	Y
Nonclinical (Pharmacology/Toxicology)	Reviewer:	Mukjerhee	Y
	TL:	Topper	Y
Statistics (carcinogenicity)	Reviewer:		
	TL:		
Immunogenicity (assay/assay validation) <i>(for BLAs/BLA efficacy supplements)</i>	Reviewer:		
	TL:		
Product Quality (CMC)	Reviewer:	Gerald Feldman	Y
	TL:	Marjorie Shapiro	N
Quality Microbiology <i>(for sterile products)</i>	Reviewer:		
	TL:		
CMC Labeling Review	Reviewer:	Kimberly Rains	Y
	TL:		
Facility Review/Inspection	Reviewer:		
	TL:		
OSE/DMEPA (proprietary name)	Reviewer:		
	TL:		
OSE/DRISK (REMS)	Reviewer:		
	TL:		
OC/OSI/DSC/PMSB (REMS)	Reviewer:		
	TL:		

Bioresearch Monitoring (OSI)	Reviewer:		
	TL:		
Controlled Substance Staff (CSS)	Reviewer:		
	TL:		
Other reviewers			
Other attendees			

FILING MEETING DISCUSSION:


<p>GENERAL</p> <ul style="list-style-type: none"> 505(b)(2) filing issues? <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Not Applicable <input type="checkbox"/> YES <input type="checkbox"/> NO <p>If yes, list issues:</p>	
<ul style="list-style-type: none"> Per reviewers, are all parts in English or English translation? <ul style="list-style-type: none"> <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO <p>If no, explain:</p>	
<ul style="list-style-type: none"> Electronic Submission comments <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Not Applicable <p>List comments:</p>	
<p>CLINICAL</p> <p>Comments:</p> <ul style="list-style-type: none"> Clinical study site(s) inspections(s) needed? <ul style="list-style-type: none"> <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO <p>If no, explain: The efficacy data for this product has been reviewed during the original BLA review for which an OSI audit was conducted.</p> 	<ul style="list-style-type: none"> <input type="checkbox"/> Not Applicable <input checked="" type="checkbox"/> FILE <input type="checkbox"/> REFUSE TO FILE <input type="checkbox"/> Review issues for 74-day letter
<ul style="list-style-type: none"> Advisory Committee Meeting needed? <ul style="list-style-type: none"> <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO <input type="checkbox"/> To be determined <p>Comments:</p> <p><i>If no, for an original NME or BLA application, include the reason. For example:</i></p>	<p>Date if known:</p> <p>Reason:</p>

<ul style="list-style-type: none"> ○ <i>this drug/biologic is not the first in its class</i> ○ <i>the clinical study design was acceptable</i> ○ <i>the application did not raise significant safety or efficacy issues</i> ○ <i>the application did not raise significant public health questions on the role of the drug/biologic in the diagnosis, cure, mitigation, treatment or prevention of a disease</i> 	
<ul style="list-style-type: none"> ● Abuse Liability/Potential <p>Comments:</p>	<input checked="" type="checkbox"/> Not Applicable <input type="checkbox"/> FILE <input type="checkbox"/> REFUSE TO FILE <input type="checkbox"/> Review issues for 74-day letter
<ul style="list-style-type: none"> ● If the application is affected by the AIP, has the division made a recommendation regarding whether or not an exception to the AIP should be granted to permit review based on medical necessity or public health significance? <p>Comments:</p>	<input checked="" type="checkbox"/> Not Applicable <input type="checkbox"/> YES <input type="checkbox"/> NO
<p>CLINICAL MICROBIOLOGY</p> <p>Comments:</p>	<input checked="" type="checkbox"/> Not Applicable <input type="checkbox"/> FILE <input type="checkbox"/> REFUSE TO FILE <input type="checkbox"/> Review issues for 74-day letter
<p>CLINICAL PHARMACOLOGY</p> <p>Comments:</p>	<input checked="" type="checkbox"/> Not Applicable <input type="checkbox"/> FILE <input type="checkbox"/> REFUSE TO FILE <input type="checkbox"/> Review issues for 74-day letter
<ul style="list-style-type: none"> ● Clinical pharmacology study site(s) inspections(s) needed? 	<input type="checkbox"/> YES <input type="checkbox"/> NO
<p>BIOSTATISTICS</p> <p>Comments:</p>	<input checked="" type="checkbox"/> Not Applicable <input type="checkbox"/> FILE <input type="checkbox"/> REFUSE TO FILE <input type="checkbox"/> Review issues for 74-day letter
<p>NONCLINICAL (PHARMACOLOGY/TOXICOLOGY)</p> <p>Comments:</p>	<input checked="" type="checkbox"/> Not Applicable <input type="checkbox"/> FILE <input type="checkbox"/> REFUSE TO FILE <input type="checkbox"/> Review issues for 74-day letter

<p>IMMUNOGENICITY (BLAs/BLA efficacy supplements only)</p> <p>Comments:</p>	<input checked="" type="checkbox"/> Not Applicable <input type="checkbox"/> FILE <input type="checkbox"/> REFUSE TO FILE <input type="checkbox"/> Review issues for 74-day letter
<p>PRODUCT QUALITY (CMC)</p> <p>Comments:</p>	<input checked="" type="checkbox"/> Not Applicable <input type="checkbox"/> FILE <input type="checkbox"/> REFUSE TO FILE <input type="checkbox"/> Review issues for 74-day letter
<p><u>Environmental Assessment</u></p> <ul style="list-style-type: none"> • Categorical exclusion for environmental assessment (EA) requested? <p>If no, was a complete EA submitted?</p> <p>If EA submitted, consulted to EA officer (OPS)?</p> <p>Comments:</p>	<input type="checkbox"/> Not Applicable <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> YES <input type="checkbox"/> NO
<p><u>Quality Microbiology (for sterile products)</u></p> <ul style="list-style-type: none"> • Was the Microbiology Team consulted for validation of sterilization? (NDAs/NDA supplements only) <p>Comments:</p>	<input checked="" type="checkbox"/> Not Applicable <input type="checkbox"/> YES <input type="checkbox"/> NO
<p><u>Facility Inspection</u></p> <ul style="list-style-type: none"> • Establishment(s) ready for inspection? ▪ Establishment Evaluation Request (EER/TBP-EER) submitted to OMPQ? <p>Comments:</p>	<input type="checkbox"/> Not Applicable <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
<p><u>Facility/Microbiology Review (BLAs only)</u></p> <p>Comments:</p>	<input checked="" type="checkbox"/> Not Applicable <input type="checkbox"/> FILE <input type="checkbox"/> REFUSE TO FILE <input type="checkbox"/> Review issues for 74-day letter

<u>CMC Labeling Review</u>	
Comments:	<input type="checkbox"/> Review issues for 74-day letter
REGULATORY PROJECT MANAGEMENT	
Signatory Authority: Sally Seymour, MD, Deputy Director for Safety	
21st Century Review Milestones (see attached) (listing review milestones in this document is optional):	
Comments:	
REGULATORY CONCLUSIONS/DEFICIENCIES	
<input type="checkbox"/>	The application is unsuitable for filing. Explain why:
<input checked="" type="checkbox"/>	The application, on its face, appears to be suitable for filing. <u>Review Issues:</u> <input checked="" type="checkbox"/> No review issues have been identified for the 74-day letter. <input type="checkbox"/> Review issues have been identified for the 74-day letter. List (optional): <u>Review Classification:</u> <input checked="" type="checkbox"/> Standard Review <input type="checkbox"/> Priority Review
ACTIONS ITEMS	
<input type="checkbox"/>	Ensure that any updates to the review priority (S or P) and classifications/properties are entered into tracking system (e.g., chemical classification, combination product classification, 505(b)(2), orphan drug).
<input type="checkbox"/>	If RTF, notify everybody who already received a consult request, OSE PM, and Product Quality PM (to cancel EER/TBP-EER).
<input type="checkbox"/>	If filed, and the application is under AIP, prepare a letter either granting (for signature by Center Director) or denying (for signature by ODE Director) an exception for review.
<input checked="" type="checkbox"/>	BLA/BLA supplements: If filed, send 60-day filing letter
<input type="checkbox"/>	If priority review: <ul style="list-style-type: none"> • notify sponsor in writing by day 60 (For BLAs/BLA supplements: include in 60-day filing letter; For NDAs/NDA supplements: see CST for choices)

	<ul style="list-style-type: none"> notify OMPQ (so facility inspections can be scheduled earlier)
<input checked="" type="checkbox"/>	Send review issues/no review issues by day 74
<input checked="" type="checkbox"/>	Conduct a PLR format labeling review and include labeling issues in the 74-day letter
<input type="checkbox"/>	BLA/BLA supplements: Send the Product Information Sheet to the product reviewer and the Facility Information Sheet to the facility reviewer for completion. Ensure that the completed forms are forwarded to the CDER RMS-BLA Superuser for data entry into RMS-BLA one month prior to taking an action [These sheets may be found at: http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/ImmediateOffice/UCM027822]
<input type="checkbox"/>	Other

Philantha Bowen		January 27, 2012
Regulatory Project Manager		Date
Ladan Jafari		January 27, 2012
Chief, Project Management Staff		Date

Appendix A (NDA and NDA Supplements only)

NOTE: The term "original application" or "original NDA" as used in this appendix denotes the NDA submitted. It does not refer to the reference drug product or "reference listed drug."

An original application is likely to be a 505(b)(2) application if:

- (1) it relies on published literature to meet any of the approval requirements, and the applicant does not have a written right of reference to the underlying data. If published literature is cited in the NDA but is not necessary for approval, the inclusion of such literature will not, in itself, make the application a 505(b)(2) application,
- (2) it relies for approval on the Agency's previous findings of safety and efficacy for a listed drug product and the applicant does not own or have right to reference the data supporting that approval, or
- (3) it relies on what is "generally known" or "scientifically accepted" about a class of products to support the safety or effectiveness of the particular drug for which the applicant is seeking approval. (Note, however, that this does not mean *any* reference to general information or knowledge (e.g., about disease etiology, support for particular endpoints, methods of analysis) causes the application to be a 505(b)(2) application.)

Types of products for which 505(b)(2) applications are likely to be submitted include: fixed-dose combination drug products (e.g., heart drug and diuretic (hydrochlorothiazide) combinations); OTC monograph deviations (see 21 CFR 330.11); new dosage forms; new indications; and, new salts.

An efficacy supplement can be either a (b)(1) or a (b)(2) regardless of whether the original NDA was a (b)(1) or a (b)(2).

An efficacy supplement is a 505(b)(1) supplement if the supplement contains all of the information needed to support the approval of the change proposed in the supplement. For example, if the supplemental application is for a new indication, the supplement is a 505(b)(1) if:

- (1) The applicant has conducted its own studies to support the new indication (or otherwise owns or has right of reference to the data/studies),
- (2) No additional information beyond what is included in the supplement or was embodied in the finding of safety and effectiveness for the original application or previously approved supplements is needed to support the change. For example, this would likely be the case with respect to safety considerations if the dose(s) was/were the same as (or lower than) the original application, and.
- (3) All other "criteria" are met (e.g., the applicant owns or has right of reference to the data relied upon for approval of the supplement, the application does not rely

for approval on published literature based on data to which the applicant does not have a right of reference).

An efficacy supplement is a 505(b)(2) supplement if:

- (1) Approval of the change proposed in the supplemental application would require data beyond that needed to support our previous finding of safety and efficacy in the approval of the original application (or earlier supplement), and the applicant has not conducted all of its own studies for approval of the change, or obtained a right to reference studies it does not own. For example, if the change were for a new indication AND a higher dose, we would likely require clinical efficacy data and preclinical safety data to approve the higher dose. If the applicant provided the effectiveness data, but had to rely on a different listed drug, or a new aspect of a previously cited listed drug, to support the safety of the new dose, the supplement would be a 505(b)(2),
- (2) The applicant relies for approval of the supplement on published literature that is based on data that the applicant does not own or have a right to reference. If published literature is cited in the supplement but is not necessary for approval, the inclusion of such literature will not, in itself, make the supplement a 505(b)(2) supplement, or
- (3) The applicant is relying upon any data they do not own or to which they do not have right of reference.

If you have questions about whether an application is a 505(b)(1) or 505(b)(2) application, consult with your OND ADRA or OND IO.

REGULATORY PROJECT MANAGER PLR FORMAT LABELING REVIEW

Application: 125276/49
Name of Drug: Actemra® (tocilizumab)
Applicant: Genentech, Inc., A Member of the Roche Group

Labeling Reviewed

Submission Date: December 12, 2011
Receipt Date: December 13, 2011

Background and Summary Description

Genentech submitted a supplemental Biologic License Application (sBLA) for Actemra® for the treatment of adults patients with moderately to severely active rheumatoid arthritis. This sBLA represents an expansion of the indication to patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).

This submission also contains a Medication Guide, Risk Management Plan, and Carton labels.


Review

The submitted labeling was reviewed in accordance with the labeling requirements listed in the “Selected Requirements for Prescribing Information (SRPI)” section of this review. Labeling deficiencies are identified in this section with an “X” in the checkbox next to the labeling requirement.

Additionally, the labeling was compared to the last approved label dated April 15, 2011, and the SEALD Label review tool.

Conclusions/Recommendations

All labeling deficiencies identified in the SRPI section of this review will be conveyed to the applicant in the 60-day letter. The applicant will be asked to resubmit labeling that addresses all identified labeling deficiencies by February 23, 2012. The resubmitted labeling will be used for further labeling discussions.

Philantha Bowen		February 6, 2012
Regulatory Project Manager		Date
Ladan Jafari		February 6, 2012
Chief, Project Management Staff		Date

Selected Requirements for Prescribing Information (SRPI)

This document is meant to be used as a checklist in order to identify critical issues during labeling development and review. For additional information concerning the content and format of the prescribing information, see regulatory requirements (21 CFR 201.56 and 201.57) and labeling guidances. When used in reviewing the PI, only identified deficiencies should be checked.

Highlights (HL)

- **General comments**

- HL must be in two-column format, with ½ inch margins on all sides and between columns, and in a minimum of 8-point font.
- HL is limited in length to one-half page. If it is longer than one-half page, a waiver has been granted or requested by the applicant in this submission.
- There is no redundancy of information.
- If a Boxed Warning is present, it must be limited to 20 lines. (Boxed Warning lines do not count against the one-half page requirement.)
- A horizontal line must separate the HL and Table of Contents (TOC).
- All headings must be presented in the center of a horizontal line, in UPPER-CASE letters and **bold** type.
- Each summarized statement must reference the section(s) or subsection(s) of the Full Prescribing Information (FPI) that contains more detailed information.
- Section headings are presented in the following order:

• Highlights Limitation Statement (required statement)
• Drug names, dosage form, route of administration, and controlled substance symbol, if applicable (required information)
• Initial U.S. Approval (required information)
• Boxed Warning (if applicable)
• Recent Major Changes (for a supplement)
• Indications and Usage (required information)
• Dosage and Administration (required information)
• Dosage Forms and Strengths (required information)
• Contraindications (required heading – if no contraindications are known, it must state “None”)
• Warnings and Precautions (required information)
• Adverse Reactions (required AR contact reporting statement)
• Drug Interactions (optional heading)
• Use in Specific Populations (optional heading)
• Patient Counseling Information Statement (required statement)
• Revision Date (required information)

- **Highlights Limitation Statement**
 - Must be placed at the beginning of HL, **bolded**, and read as follows: “**These highlights do not include all the information needed to use (insert name of drug product in UPPER CASE) safely and effectively. See full prescribing information for (insert name of drug product in UPPER CASE).**”

- **Product Title**
 - Must be **bolded** and note the proprietary and established drug names, followed by the dosage form, route of administration (ROA), and, if applicable, controlled substance symbol.

- **Initial U.S. Approval**
 - The verbatim statement “Initial U.S. Approval” followed by the 4-digit year in which the FDA initially approved of the new molecular entity (NME), new biological product, or new combination of active ingredients, must be placed immediately beneath the product title line. If this is an NME, the year must correspond to the current approval action.

- **Boxed Warning**
 - All text in the boxed warning is **bolded**.
 - Summary of the warning must not exceed a length of 20 lines.
 - Requires a heading in UPPER-CASE, **bolded** letters containing the word “**WARNING**” and other words to identify the subject of the warning (e.g., “**WARNING: LIFE-THREATENING ADVERSE REACTIONS**”).
 - Must have the verbatim statement “*See full prescribing information for complete boxed warning.*” If the boxed warning in HL is identical to boxed warning in FPI, this statement is not necessary.

- **Recent Major Changes (RMC)**
 - Applies only to supplements and is limited to substantive changes in five sections: Boxed Warning, Indications and Usage, Dosage and Administration, Contraindications, and Warnings and Precautions.
 - The heading and, if appropriate, subheading of each section affected by the recent change must be listed with the date (MM/YYYY) of supplement approval. For example, “Dosage and Administration, Coronary Stenting (2.2) --- 2/2010.”
 - For each RMC listed, the corresponding new or modified text in the FPI must be marked with a vertical line (“margin mark”) on the left edge.
 - A changed section must be listed for at least one year after the supplement is approved and must be removed at the first printing subsequent to one year.
 - Removal of a section or subsection should be noted. For example, “Dosage and

Administration, Coronary Stenting (2.2) --- removal 2/2010.”

- **Indications and Usage**

- If a product belongs to an established pharmacologic class, the following statement is required in HL: [Drug/Biologic Product) is a (name of class) indicated for (indication(s)].” Identify the established pharmacologic class for the drug at:
<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm>.

- **Contraindications**

- This section must be included in HL and cannot be omitted. If there are no contraindications, state “None.”
- All contraindications listed in the FPI must also be listed in HL.
- List known hazards and not theoretical possibilities (i.e., hypersensitivity to the drug or any inactive ingredient). If the contraindication is not theoretical, describe the type and nature of the adverse reaction.
- For drugs with a pregnancy Category X, state “Pregnancy” and reference Contraindications section (4) in the FPI.

- **Adverse Reactions**

- Only “adverse reactions” as defined in 21 CFR 201.57(a)(11) are included in HL. Other terms, such as “adverse events” or “treatment-emergent adverse events,” should be avoided. Note the criteria used to determine their inclusion (e.g., incidence rate greater than X%).
- For drug products other than vaccines, the verbatim **bolded** statement, “**To report SUSPECTED ADVERSE REACTIONS, contact (insert name of manufacturer) at (insert manufacturer’s phone number) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch**” must be present. Only include toll-free numbers.

- **Patient Counseling Information Statement**

- Must include the verbatim statement: “**See 17 for Patient Counseling Information**” or if the product has FDA-approved patient labeling: “**See 17 for Patient Counseling Information and (insert either “FDA-approved patient labeling” or “Medication Guide”)**”.

- **Revision Date**

- A placeholder for the revision date, presented as “Revised: MM/YYYY or Month Year,” must appear at the end of HL. The revision date is the month/year of application or supplement approval.

Contents: Table of Contents (TOC)

- The heading **FULL PRESCRIBING INFORMATION: CONTENTS** must appear at the beginning in UPPER CASE and **bold** type.
- The section headings and subheadings (including the title of boxed warning) in the TOC must match the headings and subheadings in the FPI.
- All section headings must be in **bold** type, and subsection headings must be indented and not bolded.
- When a section or subsection is omitted, the numbering does not change. For example, under Use in Specific Populations, if the subsection 8.2 (Labor and Delivery) is omitted, it must read:
 - 8.1 Pregnancy
 - 8.3 Nursing Mothers (not 8.2)
 - 8.4 Pediatric Use (not 8.3)
 - 8.5 Geriatric Use (not 8.4)
- If a section or subsection is omitted from the FPI and TOC, the heading “**Full Prescribing Information: Contents**” must be followed by an asterisk and the following statement must appear at the end of TOC: “*Sections or subsections omitted from the Full Prescribing Information are not listed.”

Full Prescribing Information (FPI)

• General Format

- A horizontal line must separate the TOC and FPI.
- The heading – **FULL PRESCRIBING INFORMATION** – must appear at the beginning in UPPER CASE and **bold** type.
- The section and subsection headings must be named and numbered in accordance with 21 CFR 201.56(d)(1).

• Boxed Warning

- Must have a heading, in UPPER CASE, **bold** type, containing the word “**WARNING**” and other words to identify the subject of the warning. Use **bold** type and lower-case letters for the text.
- Must include a brief, concise summary of critical information and cross-reference to detailed discussion in other sections (e.g., Contraindications, Warnings and Precautions).

- **Contraindications**

- For Pregnancy Category X drugs, list pregnancy as a contraindication.

- **Adverse Reactions**

- Only “adverse reactions” as defined in 21 CFR 201.57(c)(7) should be included in labeling. Other terms, such as “adverse events” or “treatment-emergent adverse events,” should be avoided.

- For the “Clinical Trials Experience” subsection, the following verbatim statement or appropriate modification should precede the presentation of adverse reactions:

“Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.”

- For the “Postmarketing Experience” subsection, the listing of post-approval adverse reactions must be separate from the listing of adverse reactions identified in clinical trials. Include the following verbatim statement or appropriate modification:

“The following adverse reactions have been identified during post-approval use of (insert drug name). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.”

- **Use in Specific Populations**

- Subsections 8.4 Pediatric Use and 8.5 Geriatric Use are required and cannot be omitted.

- **Patient Counseling Information**

- This section is required and cannot be omitted.

- Must reference any FDA-approved patient labeling, including the type of patient labeling. The statement “See FDA-approved patient labeling (insert type of patient labeling).” should appear at the beginning of Section 17 for prominence. For example:

- “See FDA-approved patient labeling (Medication Guide)”
- “See FDA-approved patient labeling (Medication Guide and Instructions for Use)”
- “See FDA-approved patient labeling (Patient Information)”
- “See FDA-approved patient labeling (Instructions for Use)”
- “See FDA-approved patient labeling (Patient Information and Instructions for Use)”